StockData
SIGYOTCSurgical & Medical Instruments & ApparatusFiscal year ends December 31

Sigyn Therapeutics, Inc.

Financials through Q3 FY2025, quarter ended Sep 30, 2025Last filing: 10-Q on Nov 14, 2025
$0.03+0.00 (0.00%)

Close on Oct 19, 2026

Market cap
$48.16K
P/E (TTM)
–
Dividend yield
–

Ownership

Institutional holdings as of Jun 30, 2026, from 13F filings

Held by institutions
3.3%
0M of 2M shares
Institutional holders
1
1 new, 0 sold out
Net institutional buying
0M
In Q2 2026
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
Brio Capital Master Fund Ltd.160,5379.99%13G (passive) amendmentDec 31, 2025

Top institutional holders

13F holdings as of Jun 30, 2026

HolderShares% of SIGYValueChange% of portfolio
Howard Capital Management Group, LLC53,0003.30%$1.35KNew0.00%

Institutional buying and selling by quarter

Positions opened, added to, reduced and closed by 13F filers

QuarterHoldersShares held% of sharesNew / addedReduced / closedShares boughtShares sold
Q2 202610M3.3%1 / 00 / 00M0M

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
Joseph Segelman
Chief Executive Officer, Director, 10% owner
Jun 23, 2017Buy+8,500$0.08$68025,021,000
Joseph Segelman
Chief Executive Officer, Director, 10% owner
Jun 23, 2017Buy+8,500$0.18$1.53K25,021,000
Joseph Segelman
CEO, Director, 10% owner
Mar 29, 2017Buy+2,500$0.12$30025,012,500
Joseph Segelman
CEO, Director, 10% owner
Dec 19, 2016Buy+5,000$0.10$50025,010,000
Joseph Segelman
CEO, Director, 10% owner
Dec 14, 2016Buy+5,000$0.10$50025,005,000

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.